Bluejay Therapeutics has reported the successful completion of a Phase Ia trial and enrolment of the initial Phase Ib cohorts for BJT-778, a monoclonal antibody targeting hepatitis B surface antigen.
BJT-778-001 is a double-blind, placebo-controlled single ascending dose study involving healthy volunteers and subjects with chronic hepatitis B (CHB) and chronic hepatitis D infection (CHD).
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
The US based company stated that BJT-778 was well tolerated, with no dose-limiting toxicities.
“We anticipate building on this success as we strive to broaden our portfolio of treatments and cures for viral and liver diseases,” said Blujay Therapeutic’s CEO Dr Keting Chu.
In August, Bluejay raised $41 million in Series B financing led by Arkin Bio Ventures.
The company has a licencing agreement with Novartis for its other CHB preclinical pipeline drug, BJT-628.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataGlobalData (GD) has identified China as an emerging innovator in the HBV therapies market, with Asia-Pacific region hosting the highest number of clinical trials in the field.
China based Jiangsu Hansoh Pharmaceutical’s Hengmu (tenofovir amibufenamide) is currently marketed in China. GD projects $732 million in sales for Hengmu in 2028.
Gilead Science’s Hepcludex (bulevirtide) is conditionally authorised in European Economic Area (EU) and the United Kingdom. However, it has not been approved by the US Food and Drug Administration (FDA).
